Semax

Semax (MEHFPGP)

An ACTH-derived nootropic peptide that dramatically upregulates BDNF and enhances cognitive performance.

100% 50% · t½ Time → Serum level
Molecular Weight
813.9 Da
Half-Life
~20 minutes (intranasal)
Typical Dose
200–600 mcg
Cycle Length
2–4 weeks

Description

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the 4–7 fragment of ACTH (adrenocorticotropic hormone), developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It has been approved in Russia for the treatment of ischemic stroke, traumatic brain injury (TBI), and cognitive disorders, and is widely used as a nootropic. Semax’s most notable property is its ability to dramatically upregulate BDNF (brain-derived neurotrophic factor) — by up to 400% in animal models — making it one of the most potent BDNF-enhancing agents known. BDNF is critical for neuroplasticity, memory consolidation, and neuroprotection. Semax also has neuroprotective effects in ischemia models, reduces oxidative stress in neural tissue, and has demonstrated anti-depressant and anxiolytic properties in addition to its cognitive-enhancing effects.

Key Characteristics

Molecular FormulaC37H51N9O10S
Molecular Weight813.9 Da
Half-Life~20 minutes (intranasal)
Administration RoutesIntranasal (preferred), Subcutaneous injection
Typical Dose200–600 mcg
Frequency1–2x daily

Investigated Benefits

  • Enhanced memory and learning
  • Increased BDNF expression
  • Neuroprotection after stroke/TBI
  • Improved focus and concentration
  • Mood enhancement

* Benefits based on preclinical/animal research unless otherwise noted.